SCHEMBL20448599

SCHEMBL20448599

CCCCCNC(=O)c1ccc(-c2cc(C(=O)NC3CC3)cc(F)c2C)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 1.00
CYP2C9 P11712 12/20 0.76
MAPK11 Q15759 3/20 0.76
BUB1 O43683 1/20 0.75
PRKACG P22612 1/20 0.75
MAPKAPK2 P49137 1/20 0.75
ACSL5 Q9ULC5 1/20 0.75
STK24 Q9Y6E0 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405486 0.93 MAPK14 (0.87) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3431414 0.90 MAPK14 (0.82) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3409067 0.89 MAPK14 (0.82) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL6873218 0.88 MAPK14 (0.84) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3426933 0.88 MAPK14 (0.78) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3430266 0.87 MAPK14 (0.77) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3427536 0.87 MAPK14 (0.84) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3408897 0.87 MAPK14 (0.84) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3429198 0.87 MAPK14 (0.78) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL20448732 0.87 MAPK14 (0.77) MAPK14CYP2C9MAPK11BUB1PRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550073-B2 Benzamide derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-02-04 US disclosed
US-10550073-B2 Benzamide derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-02-04 US disclosed
US-20180312462-A1 BENZAMIDE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2018-11-01 US disclosed
EP-3357916-A1 BENZAMIDE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2018-08-08 EP disclosed
EP-3357916-A1 BENZAMIDE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2018-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312462-A1 BENZAMIDE DERIVATIVE CYP3A5, ABCB1, CYP2D6 MAPK14 3791/4885CYP2C9 36/4885MAPK11 4212/4885
US-10550073-B2 Benzamide derivative CYP3A5, ABCB1, CYP2D6 MAPK14 3791/4885CYP2C9 36/4885MAPK11 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.